CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

halobetasol propionate and tazarotene

Last Updated: May 31, 2019
Result type: Reports
Project Number: SR0600-000
Product Line: Reimbursement Review

Generic Name: halobetasol propionate and tazarotene

Brand Name: TBC

Manufacturer: Bausch Health, Canada Inc.

Therapeutic Area: Psoriasis, moderate to severe plaque

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Topical treatment of moderate-to-severe plaque psoriasis.

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJanuary 07, 2019
Submission receivedFebruary 04, 2019

- Voluntarily withdrawn by the manufacturer on 2019-Feb-19